Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CNCB Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 4
Average round size
The average size of a deal this fund participated in
Portfolio companies 4
Lead investments 0
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Medical Device

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CNCB Capital:
Typical Co-investors
CNCB Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CNCB Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AIA Konica Minolta Digital Health Accelerator Central, Central Region, Singapore
Antagene France, Limonest, Rhone-Alpes
Anvil Investment Associates -
Architel Dallas, Texas, United States
Capital Nature Israel, Tel Aviv, Tel Aviv District
Creative Connectors -
Divine interVentures California, Oakland, United States
FinTech Growth Fund Europe GmbH & Co KG Austria, Vienna
Geometry Venture Development Istanbul, Sariyer, Turkey
Haochejiadao Beijing, Beijing, China
Mosaic Ventures England, London, United Kingdom
Navteq Chicago, Illinois, United States
Novabase Capital Lisboa, Lisbon, Portugal
Phatisa Bryanston, Gauteng, South Africa
Rainmaker Systems California, Campbell, United States
Sabre Partners India, Maharashtra, Mumbai
Selenium Enterprise Management Center China, Shanghai
We Ventures -
Xiaozhan Jiaoyu China, Shanghai
ZZ Capital International -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

HaploX Biotechnology

Health Care
26 Jul 2022 Futian District, Guangdong Province, China

Green Bamboo Bio

Health Care
Health Diagnostics
30 Jun 2022 Beijing, Beijing, China

IASO Biotherapeutics

$108M16 Sep 2021 Xuanwu District, Jiangsu, China

Broncus Technologies

Health Care
Medical Device
14 Oct 2020 Mountain View, California, United States
IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CNCB Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: